CORRECTING and REPLACING Cardima Enters Into $3 Million Loan Agreement
FREMONT, Calif.--(BUSINESS WIRE)--Sept. 1, 2005--In BW5233 issued Aug. 31, 2005: Please replace the release dated August 31, 2005 with the following corrected version due to multiple revisions.
The corrected release reads:
CARDIMA ENTERS INTO $3 MILLION LOAN AGREEMENT
Cardima, Inc. (OTC: CRDM), developer of the REVELATION(R) Tx, REVELATION(R) T-Flex and REVELATION(R) Helix microcatheter systems for the treatment of atrial fibrillation has entered into a $3 million loan agreement with Apix International Limited. This figure is an increase from the $2 million in financing that was previously reported on August 15.
In accordance with this agreement, which was dated on August 28, 2005 Cardima received a $500,000 bridge loan after signing the original Bridge Loan Agreement and IP Security Agreement on August 15, 2005. The Company then received an additional $500,000 on Closing after signing of the Final Term Sheet together with the Loan Agreement, IP Security Agreement and other documents required for Closing on August 28, 2005. The remainder of the loan will be received as follows: $500,000 on or after September 12, 2005, $500,000 on or after October 12, 2005, $350,000 on or after November 18, 2005, $350,000 on or after December 18, 2005, $300,000 on or after January 18, 2006.
The completion of this loan agreement together with aggressive near term cost reduction measures will allow the Company to focus on its critical near term goals. These include the continuation of discussions with the FDA regarding regulatory approval for the Revelation Tx microcatheter systems for the treatment of atrial fibrillation. The Company intends to focus intensively on the regulatory approval process and direct its near term resources accordingly. The Company is also in discussions with medical device companies regarding potential partnering or the potential sale of some of its product lines and intellectual property and the loan will permit the Company to continue these active discussions. The Company also intends to work closely with its Japanese distributor to expand this market for its diagnostic catheter products.
- All of the funds to be provided by Apix will bear interest at a rate of 10 percent per annum, will be evidenced by a Loan Agreement and will be secured by a first lien on all of the Company's assets and intellectual property. Facility and exit fees and accrued interest due under the loan, if any, is convertible into shares of Cardima's common stock at a rate of $0.10 per share.
- Additionally, Cardima will provide the lender with Warrant to purchase capital stock in the amount of 30,000,000, with a strike price of $0.10. The financing facility has a term of 6 months ending on February 28, 2006.
- The Company is subject to certain reporting covenants such as the timely filing of financial reports with the Securities and Exchange Commission, monthly financial reporting deadlines and collateral reporting.
Additional details about these events can be found in the form 8-K to be filed by Cardima Inc. with the Securities and Exchange Commission on September 1, 2005.
About Cardima
Cardima, Inc. has developed the PATHFINDER® and REVELATION® Series of diagnostic catheters, the INTELLITEMP® Energy Management Device, and the Surgical Ablation System (SAS). All of these devices are CE marked and received U.S. FDA 510(k) clearance. The REVELATION® Series of ablation catheters with the INTELLITEMP® EP Energy Management Device was developed and marketed for the treatment of atrial fibrillation (AF) after receiving CE mark approval in Europe; it is not currently available in the U.S.
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by such forward-looking statements. Potential risks and uncertainties include: the uncertainties associated with the prospects for FDA approval of any new devices; the prospect for any future clinical trials or regulatory activities; the risk that the Company will not be able to raise additional capital in the immediate term as needed to continue operations and the risk that we will be unable to secure a strategic transaction involving the Surgical Ablation System. Additional risks and uncertainties are set forth in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006, the Company's Quarterly Report on Form 10-QSB for the third quarter ended September 30, 2007, and in the Company's subsequent SEC filings. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.